As of 2026-05-24, the EV/EBITDA ratio of Syros Pharmaceuticals Inc (SYRS) is 0.18. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SYRS's latest enterprise value is -17.19 mil USD. SYRS's TTM EBITDA according to its financial statements is -95.71 mil USD. Dividing these 2 quantities gives us the above SYRS EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 11.4x - 14.8x | 14.7x |
| Forward P/E multiples | 14.2x - 17.9x | 15.9x |
| Fair Price | (29,351.84) - (30,480.72) | (31,609.61) |
| Upside | -25044328.5% - -26007543.2% | -26970757.8% |
| Date | EV/EBITDA |
| 2026-05-19 | 0.18 |
| 2026-05-18 | 0.18 |
| 2026-05-15 | 0.18 |
| 2026-05-14 | 0.18 |
| 2026-05-13 | 0.18 |
| 2026-05-12 | 0.18 |
| 2026-05-11 | 0.18 |
| 2026-05-08 | 0.18 |
| 2026-05-07 | 0.18 |
| 2026-05-06 | 0.18 |
| 2026-05-05 | 0.18 |
| 2026-05-04 | 0.18 |
| 2026-05-01 | 0.18 |
| 2026-04-30 | 0.18 |
| 2026-04-29 | 0.18 |
| 2026-04-28 | 0.18 |
| 2026-04-27 | 0.18 |
| 2026-04-24 | 0.18 |
| 2026-04-23 | 0.18 |
| 2026-04-22 | 0.18 |
| 2026-04-21 | 0.18 |
| 2026-04-20 | 0.18 |
| 2026-04-17 | 0.18 |
| 2026-04-16 | 0.18 |
| 2026-04-15 | 0.18 |
| 2026-04-14 | 0.18 |
| 2026-04-13 | 0.18 |
| 2026-04-10 | 0.18 |
| 2026-04-09 | 0.18 |
| 2026-04-08 | 0.18 |
| 2026-04-07 | 0.18 |
| 2026-04-06 | 0.18 |
| 2026-04-02 | 0.18 |
| 2026-04-01 | 0.18 |
| 2026-03-31 | 0.18 |
| 2026-03-30 | 0.18 |
| 2026-03-27 | 0.18 |
| 2026-03-26 | 0.18 |
| 2026-03-25 | 0.18 |
| 2026-03-24 | 0.18 |
| 2026-03-23 | 0.18 |
| 2026-03-20 | 0.18 |
| 2026-03-19 | 0.18 |
| 2026-03-18 | 0.18 |
| 2026-03-17 | 0.18 |
| 2026-03-16 | 0.18 |
| 2026-03-13 | 0.18 |
| 2026-03-12 | 0.18 |
| 2026-03-11 | 0.18 |
| 2026-03-10 | 0.18 |